Related Experiment Video
Updated: Jun 23, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report
Alina Adeel1, Ming D Qu1, Efaza Siddiqui2
1Division of Infectious Disease & Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Abstract:
Rezafungin is a semisynthetic, long-acting echinocandin with broad-spectrum activity against many Candida species and Aspergillus species, including a subset of drug-resistant strains. It is currently in phase III trials and was found to be safe and effective for the treatment of candidemia and/or invasive Candida infections in a phase II trial. However, there are no long-term safety or efficacy data. We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over 1 year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material.
More Related Videos
Related Concept Videos
Cryptococcal Meningitis
Candidiasis
Antifungal Agents

